Chemical formula: C₁₆H₁₅N₃ Molecular mass: 249.31 g/mol PubChem compound: 3241
Epinastine is a topically active, direct H1-receptor antagonist and an inhibitor of the release of histamine from the mast cell. Epinastine is selective for the histamine H1-receptor and has affinity for the histamine H2receptor. Epinastine also possesses affinity for the α1, α2, and 5-HT2–receptors.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| R06AX24 | Epinastine | R Respiratory system → R06 Antihistamines for systemic use → R06A Antihistamines for systemic use → R06AX Other antihistamines for systemic use |
| S01GX10 | Epinastine | S Sensory organs → S01 Ophthalmologicals → S01G Decongestants and antiallergics → S01GX Other antiallergics |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| ELESTAT Ophthalmic solution | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| RELESTAT Eye drops, solution | Health Products Regulatory Authority (IE) | MPI, EU: SmPC |
Epinastine is an active ingredient of these brands:
United States (US)
Austria (AT)
Brazil (BR)Ecuador (EC)
France (FR)
Hong Kong (HK)
Ireland (IE)
Israel (IL)
Japan (JP)
Mexico (MX)
New Zealand (NZ)
Poland (PL)
Singapore (SG)
South Africa (ZA)
Spain (ES)
Turkey (TR)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
